Is Astraea profitable?

No revenue figures for Astraea have been independently verified. As of May 18, 2026 YC listed it as a 2-person, San Francisco-based YC P26 startup with no disclosed funding round, customer logos, or revenue, per Y Combinator's own directory.

How many employees does Astraea have?

Y Combinator's Health Tech directory listed Astraea at 2 employees, based in San Francisco, as of May 18, 2026. In June 2026 it posted a Founding Engineer role ($120K to $300K plus 0.5 to 2 percent equity), signaling plans to grow beyond the founder pair.

Who is Astraea's biggest competitor?

Saama is the closest competitor, with a live SDTM Navigator (July 2025) and ADaM Navigator (December 2025) automating the same clinical biometrics pipeline Astraea targets, and claims of Top-5 global pharma usage as of September 2025 (vendor-claimed).

Could AI replace Astraea's own product?

Astraea's product is itself an AI system automating clinical biometrics, meaning its core service is exposed to commoditization by larger incumbents like Saama and Certara or by frontier reasoning models applied to public CDISC standards, since it has no proprietary data or verified moat as of mid-2026.

Is Astraea funded, and how much?

No confirmed seed or Series A round has been publicly verified. A Caplight page showed '$13.5M total funding' dated February 20, 2024, but this figure is flagged as likely misattributed to an unrelated Virginia entity, not the SF-based YC P26 clinical-AI company.

What does Astraea actually build?

Astraea builds an AI platform that ingests clinical trial protocols, CRFs, SAPs, and raw data to generate SDTM/ADaM datasets, TFLs, Define-XML, and submission-ready outputs via multi-agent AI, initially targeting oncology and rare-disease Phase II/III studies, per its own site.

YC Spring 2026 · United States

Astraea

Astraea builds AI agents that automate clinical trial biometrics and submission-ready data packages for pharma.

Protection under test

Assessed 27 July 2026 · Evidence as of 27 July 2026

Something worth protecting exists and is being tested right now.

On the recordSince 27 July 2026 · Checkable from Q4 2027 · Every call on the record Checkpoint: Astraea's window to land a named biotech design partner and complete one FDA-accepted submission

The call

Astraea targets a real bottleneck in clinical data work, but Saama and Certara already ship similar tools to the biggest buyers, and no named client or completed submission has surfaced yet.

Astraea speeds up the nine-month process of converting clinical trial data into regulatory-ready documents, which is a real bottleneck that costs pharma companies time and money. However, competitors like Saama and Certara have already shipped working versions to major pharmaceutical companies, and there is no technical barrier stopping large software vendors or AI models from building the same thing. The one thing that could prove Astraea belongs in this market is a public announcement that a biotech company has completed and filed an actual FDA submission using Astraea's software, combined with proof of funding. Right now the company's track record and financial backing remain unconfirmed.

Why

AI pressure: Frontier agentic coding models (Anthropic, OpenAI) applied to public CDISC standards. Once general models can reliably generate SDTM/ADaM code, Astraea's core automation stops being special. Could AI do the core job? Yes, likely.

Bigger players: Saama (SDTM/ADaM Navigators) and Certara/Formedix (Pinnacle21 + Veeva RIM). Both already sell live AI biometrics tools to top pharma, the same buyers Astraea is trying to reach. Could a giant copy it? Yes, easily.

What protects it. FDA audit-trail and liability requirements slow switching, but nothing yet ties that protection to Astraea specifically.

What would change this call

A named biotech sponsor publicly confirms using Astraea for a Phase II/III submission within 12 months. Would show real paying customers exist beyond vendor claims.
Saama or Certara announces full protocol-to-submission orchestration, not just point tools. Would show incumbents closing the wedge Astraea depends on.
Astraea announces a verifiable funding round from a named investor. Would show outside capital backing beyond the disputed Caplight figure.

Key numbers

Astraea has 2 employees (2026-05-18)
Saama cut ADaM spec time from 27 to 9 days (2025-07-02)
Founding Engineer pay $120K-$300K plus 0.5-2% equity (2026-06-08)

Named risks

No proprietary data or demonstrated moat beyond a 2-person pre-funding team. Severity: high
Forward-deployed, data-never-leaves architecture blocks the company's own data flywheel. Severity: high
Incumbents Saama and Certara have already shipped comparable SDTM/ADaM automation to top pharma. Severity: high
Frontier AI models could commoditize public CDISC-standard orchestration tasks. Severity: medium
No independently verified customers, revenue, or funding round as of July 2026. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Saama	losing to	Live SDTM Navigator (Jul 2025) and ADaM Navigator (Dec 2025), claimed Top-5 pharma use, vs Astraea 2-person pre-funding team
Certara/Formedix	losing to	Certara folded Formedix into Pinnacle 21 (2023) and integrated CoAuthor with Veeva RIM Oct 2025, extending full-pipeline reach
Medidata, Veeva, IQVIA, ICON	contesting	Named as dominant eClinical/CTMS/EDC vendors with existing enterprise trust Astraea lacks as of 2026

Questions people ask

Is Astraea profitable?: No revenue figures for Astraea have been independently verified. As of May 18, 2026 YC listed it as a 2-person, San Francisco-based YC P26 startup with no disclosed funding round, customer logos, or revenue, per Y Combinator's own directory.
How many employees does Astraea have?: Y Combinator's Health Tech directory listed Astraea at 2 employees, based in San Francisco, as of May 18, 2026. In June 2026 it posted a Founding Engineer role ($120K to $300K plus 0.5 to 2 percent equity), signaling plans to grow beyond the founder pair.
Who is Astraea's biggest competitor?: Saama is the closest competitor, with a live SDTM Navigator (July 2025) and ADaM Navigator (December 2025) automating the same clinical biometrics pipeline Astraea targets, and claims of Top-5 global pharma usage as of September 2025 (vendor-claimed).
Could AI replace Astraea's own product?: Astraea's product is itself an AI system automating clinical biometrics, meaning its core service is exposed to commoditization by larger incumbents like Saama and Certara or by frontier reasoning models applied to public CDISC standards, since it has no proprietary data or verified moat as of mid-2026.
Is Astraea funded, and how much?: No confirmed seed or Series A round has been publicly verified. A Caplight page showed '$13.5M total funding' dated February 20, 2024, but this figure is flagged as likely misattributed to an unrelated Virginia entity, not the SF-based YC P26 clinical-AI company.
What does Astraea actually build?: Astraea builds an AI platform that ingests clinical trial protocols, CRFs, SAPs, and raw data to generate SDTM/ADaM datasets, TFLs, Define-XML, and submission-ready outputs via multi-agent AI, initially targeting oncology and rare-disease Phase II/III studies, per its own site.

Timeline

2026-06-08Astraea posts Founding Engineer role in SF, $120K-$300K plus 0.5-2% equity
2026-05-18YC directory lists Astraea at 2 employees, San Francisco
2026-05-13Astraea publicly launches via Launch YC as YC P26 company
2026-04-28FDA announces steps toward real-time clinical trials (RTCT) initiative
2025-12-02Saama's ADaM Navigator goes live (vendor-claimed)
2025-10-21Certara integrates CoAuthor generative-AI tool with Veeva RIM
2025-07-02Saama's SDTM Navigator case study recap published
2023Certara acquires Formedix, folds SDTM tool into Pinnacle 21

Revision history

27 July 2026

First assessed. Protection under test. The text above is fixed as of this date and is not edited afterwards.

In the same band

Ploy Standout Playabl.ai